In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV).

JUAN M. LLABOT; INÉS LUIS DE REDIN; MAITE AGÜEROS; MARÍA JOSÉ DÁVILA CABALLEROB , ; CAROLINA BOIERO; JUAN M. IRACHE; DANIEL ALLEMANDI

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

EDITIONS SANTE

Año: 2019 p. 379 - 379

1773-2247

he aim of this work was to study the preparation process and the in vitro release of human serum albumin nanoparticles stabilized by Gantrez® ES-425, which was loaded with antiangiogenic drugs (suramin and bevacizumab). Nanoparticles were prepared by coacervation and stabilized with Gantrez®ES-425(Nps-Ga). As control, albumin nanoparticles cross-linked with glutaraldehyde (Nps-Glu) were prepared. Nps-Ga displayed a mean size of about 210 nm whereas Nps-Glu showed a mean size of 158 nm. For suramin-loaded nanoparticles, the stabilization process did not show any significant effect on the drug with neither glutaraldehyde nor Gantrez®. On the contrary, for bevacizumab, only nanoparticles stabilized with Gantrez® displayed important payloads (97 μg/mg nanoparticle) of the active form of the antibody. For nanoparticles with glutaraldehyde, only a very low amount of the loaded bevacizumab remained active. Regarding the in vitro release studies,suramin showed a release mechanism influen